keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/28427296/predictors-of-response-to-therapy-with-omalizumab-in-patients-with-severe-allergic-asthma-a-real-life-study
#1
Maria Kallieri, Andriana I Papaioannou, Evgenia Papathanasiou, Polyxeni Ntontsi, Spyridon Papiris, Stelios Loukides
INTRODUCTION: Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody, used for the treatment of severe refractory allergic asthma. However, not all patients with IgE levels within the limits of administration, respond to treatment. The aim of the present study, was to determine clinical and inflammatory characteristics that could predict response to omalizumab. METHODS: We studied retrospectively patients treated with omalizumab as per GINA guidelines in one asthma tertiary referral center...
April 21, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28414061/mechanistic-correlates-of-clinical-responses-to-omalizumab-in-the-setting-of-oral-immunotherapy-for-milk-allergy
#2
Pamela A Frischmeyer-Guerrerio, Madhan Masilamani, Wenjuan Gu, Erica Brittain, Robert Wood, Jennifer Kim, Kari Nadeau, Kirsi M Jarvinen, Alexander Grishin, Robert Lindblad, Hugh A Sampson
BACKGROUND: In our recent clinical trial, the addition of omalizumab to oral immunotherapy (OIT) for milk allergy improved safety but no significant clinical benefit was detected. OBJECTIVE: To investigate mechanisms by which omalizumab modulates immunity in the context of OIT, and to identify baseline biomarkers that predict subgroups of patients most likely to benefit from omalizumab. METHODS: Blood was obtained at baseline and multiple time-points during a placebo-controlled trial of OIT for milk allergy where subjects were randomized to receive omalizumab or placebo...
April 13, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28413387/successful-treatment-of-a-bullous-pemphigoid-patient-with-rituximab-who-was-refractory-to-corticosteroid-and-omalizumab-treatments
#3
Aslı Bilgiç Temel, Cumhur Ibrahim Bassorgun, Ayşe Akman-Karakaş, Erkan Alpsoy, Soner Uzun
Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reported to be effective in various autoimmune diseases, including autoimmune bullous dermatoses. A specific protocol for the use of rituximab to treat BP patients is not yet available. There are only small case series and case reports about the efficacy and safety of rituximab in BP...
January 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/28406319/benralizumab-as-a-potential-treatment-of-asthma
#4
Sabina Antonela Antoniu
Current anti-inflammatory asthma therapies including inhaled corticosteroids and leukotriene modifiers, are not always able to appropriately control the disease and other approaches are needed. These therapies specific target IgE (omalizumab) or IL-5 (mepolizumab). However, there is research underway investigating interleukin-based monoclonal antibodies such as benralizumab, an anti-IL-5R monoclonal antibody which is currently in phase III clinical development. Areas covered: This review summarizes the existing preclinical and clinical data of benralizumab...
April 19, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28390587/clinical-features-of-adolescents-with-chronic-idiopathic-or-spontaneous-urticaria-review-of-omalizumab-clinical-trials
#5
Stanley Goldstein, Susan Gabriel, Farid Kianifard, Benjamin Ortiz, David P Skoner
BACKGROUND: Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL. OBJECTIVE: To describe the baseline clinical profile of adolescent patients with CIU enrolled in the omalizumab trials to add to the limited literature available on CIU in this population. METHODS: Data for patient demographics, baseline clinical disease characteristics, medical history, and previous CIU medication information (not efficacy assessments) from phase 3 omalizumab trials were pooled and descriptive statistical analyses performed for adolescent (12 to <18 years old) and adult (≥18 years old) subgroups...
April 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28389393/omalizumab-is-effective-in-cold-urticaria-results-of-a-randomized-placebo-controlled-trial
#6
Martin Metz, Andrea Schütz, Karsten Weller, Marina Gorczyza, Sebastian Zimmer, Petra Staubach, Hans F Merk, Marcus Maurer
No abstract text is available yet for this article.
April 4, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28389391/omalizumab-is-effective-in-symptomatic-dermographism-results-of-a-randomized-placebo-controlled-trial
#7
Marcus Maurer, Andrea Schütz, Karsten Weller, Nicole Schoepke, Adriane Peveling-Oberhag, Petra Staubach, Sabine Müller, Thilo Jakob, Martin Metz
No abstract text is available yet for this article.
April 4, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28387160/long-term-treatment-in-pediatric-asthma-an-update-on-chemical-pharmacotherapy
#8
Carolina Vitale, Angelantonio Maglio, Corrado Pelaia, Alessandro Vatrella
Asthma is the most common chronic disease in childhood, affecting approximately 10% of all children, and is the leading cause of hospitalization in developed countries. In this paper we aimed to review the evidence on chemical pharmacotherapy for long-term treatment of pediatric asthma, according to the latest updates. Area covered: Long-term treatment, essential for controlling symptoms and reducing future risks including exacerbations and decline in lung function, includes control agents such as inhaled corticosteroids, long-acting beta2-adrenergic agonists, and leukotriene modifiers...
April 20, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28380487/effectiveness-of-autologous-whole-blood-injections-in-patients-with-refractory-chronic-spontaneous-urticaria
#9
Nikolaos Aggelis Kitsioulis, Paraskevi Xepapadaki, Aggeliki-Victoria Roussaki-Schulze, Nikolaos Papadopoulos, Efterpi Zafiriou
BACKGROUND: Nonsedating antihistamines are the treatment of choice for chronic spontaneous urticaria (CSU), while omalizumab and immunosuppressants have also been approved as an add-on treatment. Autologous whole-blood injection (AWBI) has been used in previous studies with ambiguous results. The aim of our study was to evaluate changes in the Urticaria Activity Score (UAS7), Dermatology Life Quality Index (DLQI), and Chronic Urticaria Quality of Life (CU-Q2oL) score, and also the association of serologic markers with disease severity measures after AWBI...
April 6, 2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28375933/use-of-biologics-in-severe-food-allergies
#10
Alessandro Fiocchi, Valentina Pecora, Rocco L Valluzzi, Vincenzo Fierro, Maurizio Mennini
PURPOSE OF REVIEW: Severe cases of food allergy account for the majority of the burden in terms of risks, quality of life, and resource expenditure. The traditional approach to these forms has been strict avoidance. More recently, Oral ImmunoTherapy (OIT) has gained a role in their management. However, in severe food allergies OIT is often infeasible. RECENT FINDINGS: Case reports, observational, and prospective studies have recently proposed different approaches to severe food allergy...
April 1, 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28366479/biologic-therapy-in-the-treatment-of-chronic-skin-disorders
#11
REVIEW
James M Fernandez, Anthony P Fernandez, David M Lang
Understanding of the immunologic pathways involved in the pathogenesis of skin-related diseases is constantly advancing. Several biologic agents play important therapeutic roles for management of patients with chronic urticaria, atopic dermatitis, and psoriasis, particularly omalizumab for antihistamine-resistant chronic urticaria, interleukin (IL)-1 inhibitors for cryopyrin-associated periodic syndrome and Schnitzler syndrome, dupilumab for recalcitrant atopic dermatitis, and IL-17 inhibitors for psoriasis...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366435/efficacy-and-safety-of-omalizumab-in-japanese-and-korean-patients-with-refractory-chronic-spontaneous-urticaria
#12
Michihiro Hide, Hae-Sim Park, Atsuyuki Igarashi, Young-Min Ye, Tae-Bum Kim, Akiko Yagami, Jooyoung Roh, Jae-Hyun Lee, Yuko Chinuki, Sang Woong Youn, Soo-Keol Lee, Naoko Inomata, Jeong-Hee Choi, Atsushi Fukunaga, Junyi Wang, Soichiro Matsushima, Steve Greenberg, Sam Khalil
BACKGROUND: Many patients with chronic spontaneous/idiopathic urticaria (CSU/CIU) do not respond adequately to treatment with non-sedating H1 antihistamines (H1AH). There are limited studies on use of omalizumab as add-on therapy for treatment of CSU in an Asian population. OBJECTIVE: The POLARIS study (NCT02329223), representing the first randomized, double-blind, placebo-controlled phase III trial of omalizumab for CSU in an Eastern Asian population, evaluated efficacy and safety of omalizumab as add-on therapy for treatment of CSU...
March 21, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28351783/-real-life-effectiveness-studies-of-omalizumab-in-adult-patients-with-severe-allergic-asthma-meta-analysis
#13
Abdulaziz Alhossan, Christopher S Lee, Karen MacDonald, Ivo Abraham
BACKGROUND: After the approval of omalizumab for severe allergic asthma, a total of 25 studies have evaluated the effectiveness of omalizumab under "real-life" conditions of heterogeneity in patients, clinicians, sites, and treatment patterns. OBJECTIVE: We conducted a meta-analysis to evaluate the effectiveness of omalizumab focusing on treatment response, lung function, quality of life, symptom control, corticosteroid use, and exacerbations and hospitalizations at 4-6, 12, and 24 months...
March 25, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28350555/apheresis-in-food-allergies
#14
Lamia Dahdah, Giovanna Leone, Mariacristina Artesani, Carla Riccardi, Oscar Mazzina
PURPOSE OF REVIEW: The prevalence of IgE-mediated food allergy and anaphylaxis has risen rapidly in developed countries, and countries with rapid industrialization may follow. Therapies include elimination diets, Oral ImmunoTherapy, and the administration of biologics, but high serum IgE levels may preclude their use. Consequently, decreasing IgE becomes a rational approach and could be obtained by immunoapheresis. The aim of this review is to evaluate the rationale and advantages of immunoapheresis...
March 27, 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28348726/targeting-patients-with-asthma-for-omalizumab-therapy-choosing-the-right-patient-to-get-the-best-value-for-money
#15
REVIEW
Abir Al Said, Breda Cushen, Richard W Costello
The asthma syndrome has many manifestations, termed phenotypes, that arise by specific cellular and molecular mechanisms, termed endotypes. Understanding an individual's asthma phenotype helps clinicians make rational therapeutic decisions while the understanding of endotypes has led to the development of specific precision medications. Allergic asthma is an example of an asthma phenotype and omalizumab, a monoclonal antibody that neutralizes serum immunoglobulin (Ig)E, is a specific targeted treatment which was developed as a result of an understanding of the endotype of allergic asthma...
February 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/28330497/atopic-dermatitis-anti-ige-paediatric-trial-adapt-the-role-of-anti-ige-in-severe-paediatric-eczema-study-protocol-for-a-randomised-controlled-trial
#16
Susan Chan, Victoria Cornelius, Tao Chen, Suzana Radulovic, Mandy Wan, Rahi Jahan, Gideon Lack
BACKGROUND: The evidence for systemic treatments for severe childhood eczema is limited and largely based on extrapolation of data from adult studies. Current therapies are often immunosuppressant and may be associated with both short- and long-term side effects. There is increasing in vitro and murine-model evidence for the role of IgE in the immunopathogenesis of atopic eczema. The aim of the study is to assess whether anti-IgE treatment (omalizumab) improves eczema, compared to placebo...
March 22, 2017: Trials
https://www.readbyqxmd.com/read/28319473/precision-medicine-in-asthma-the-role-of-bronchial-thermoplasty
#17
Amber J Oberle, Praveen Mathur
PURPOSE OF REVIEW: The inflammatory makeup of severe asthma is heterogeneous. Identification of the predominant cellular endotype via biomarkers can aid in the selection of more advanced therapies. This review is clinically focused on how to use these biomarkers to help select between biologic agents and/or bronchial thermoplasty. RECENT FINDINGS: Several Th2 biomarkers exist for the detection of eosinophilic disease; however, the best biomarker for clinical practice is debatable depending upon local resources...
May 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/28314658/management-of-chronic-inducible-urticaria-according-to-the-guidelines-a-prospective-controlled-study
#18
Emek Kocatürk, Pelin Kuteyla Can, Pırıl Etikan Akbas, Mehmet Copur, Ece Nur Degirmentepe, Kübra Kızıltac, Ralfi Singer
BACKGROUND: The recommended treatment approach in chronic inducible urticarias (CIndU) is the same as that for chronic spontaneous urticaria (CSU). But there is a lack of controlled trials assessing efficacy of available treatment options. OBJECTIVE: We aimed to evaluate the efficacy of treatment algorithm recommended by the guidelines and comparison of treatment responses in CIndU vs CSU. METHODS: This prospective parallel group controlled study included 70 CIndU and 66 CSU patients...
March 1, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28303277/basophil-fc%C3%AE%C2%B5ri-expression-in-chronic-spontaneous-urticaria-a-potential-immunological-predictor-of-response-to-omalizumab-therapy
#19
Gustavo Deza, Marta Bertolín-Colilla, Ramon M Pujol, Laia Curto-Barredo, Dulce Soto, Maribel García, Pilar Hernández, Ramon Gimeno, Ana M Giménez-Arnau
Although the efficacy of omalizumab has been clearly demonstrated in the treatment of chronic spontaneous urticaria (CSU), its mechanism of action, which results in improvement in CSU symptoms, is not entirely understood. This study investigated the effect of omalizumab on expression of the high-affinity IgE receptor (FcεRI) on blood basophils from patients with active CSU, and its association with the clinical response. Patients exhibiting significant clinical improvement showed a sharp reduction in the levels of basophil FcεRI after 4 weeks, which was maintained throughout the total duration of the treatment...
March 17, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28303134/bronchial-epithelial-cells-from-asthmatic-patients-display-less-functional-hla-g-isoform-expression
#20
Federico Carlini, Christophe Picard, Céline Garulli, David Piquemal, Pierre Roubertoux, Jacques Chiaroni, Pascal Chanez, Delphine Gras, Julie Di Cristofaro
Not all asthmatic patients adequately respond to current available treatments, such as inhaled corticosteroids or omalizumab(®). New treatments will aim to target the bronchial epithelium-immune response interaction using different pathways. HLA-G is involved in immunomodulation and may promote epithelial cell differentiation and proliferation. HLA-G protein has several isoforms generated by alternative splicing that might have differential functionalities. HLA-G protein expression and genetic polymorphisms have been reported to be associated with asthma...
2017: Frontiers in Immunology
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"